Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy-Reference-Cited by-同舟云学术

Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy

Published:2023-07-25 Issue:10 Volume:40 Page:4189-4215
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Goldschmidt Jerome,Hart Lowell,Scott Jeffrey,Boykin Kristen,Bailey Ray,Heritage Trevor,Lopez-Gonzalez Lorena,Zhou Zheng-Yi,Edwards Marie Louise,Monnette Alisha,Ogbonnaya Augustina,Deyoung Kathryn,Venkatasetty Divea,Shi Ping,Aton Lindsay,Huang Huan,Conkling Paul R.,Gordan Lucio

Funder

G1 Therapeutics

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-023-02601-2.pdf

Reference41 articles.

1. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7(1):3.

2. Zugazagoitia J, Paz-Ares L. Extensive-stage small-cell lung cancer: first-line and second-line treatment options. J Clin Oncol. 2022;40(6):671–80.

3. US Food and Drug Administration. Atezolizumab product label. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761034s047lbl.pdf. Accessed 15 Mar 2023.

4. US Food and Drug Administration. Durvalumab product label. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761069s033lbl.pdf. Accessed 15 Mar 2023.

5. Das M, Padda SK, Weiss J, Owonikoko TK. Advances in treatment of recurrent small cell lung cancer (SCLC): insights for optimizing patient outcomes from an expert roundtable discussion. Adv Ther. 2021;38(11):5431–51.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proteomic Analysis Reveals Trilaciclib-Induced Senescence;Molecular & Cellular Proteomics;2024-06

2. Proteomic Analysis Reveals Trilaciclib-Induced Senescence;2024-03-14